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Abstract  
Background: Helicobacter pylori (H pylori) is associated with peptic ulcer disease and gastric cancer.  
Aim: To test how various lengths of delays in H pylori eradication therapy influence the risk of recurrent peptic ulcer, ulcer adverse events and 
gastric cancer. 
Methods: This population-based nationwide Swedish cohort study included 29,032 patients receiving H pylori eradication therapy after peptic 
ulcer disease in 2005-2013. Pre-defined time intervals between date of peptic ulcer diagnosis and date of eradication therapy were analysed in 
relation to study outcomes. Cox regression provided hazard ratios (HRs) and 95% confidence intervals (95% CIs), adjusted for age, sex, 
comorbidity, history of ulcer disease, use of ulcerogenic drugs, and use of proton pump inhibitors (PPIs).  
Results: Compared to eradication therapy within 7 days of peptic ulcer diagnosis, eradication therapy within 8 to 30, 31 to 60, 61 to 365, and 
>365 days corresponded with HRs of recurrent ulcer of 1·17 (95% CI, 1·08-1·25), 2·37 (95%,CI, 2·16-2·59), 2·96 (95%,CI, 2·76-3·16), and 3·55 
(95% CI, 3·33-3·79), respectively. The corresponding HRs for complicated ulcer were 1·55 (95% CI, 1·35-1·78), 3·19 (95% CI, 2·69-3·78), 4·00 
(95% CI, 3·51-4·55), and 6·14, 95% CI, 5·47-6·89), respectively. For gastric cancer, the corresponding HRs were 0·85 (95% CI, 0·32-2·23), 1·31 
(95% CI, 0·31-5·54), 3·64 (95% CI, 1·55-8·56), and 4·71 (95% CI, 2·36-9·38), respectively. 
Conclusions: Delays in H pylori eradication therapy after peptic ulcer diagnosis time-dependently increase the risk of recurrent ulcer, and even 
more so for complicated ulcer, starting from delays of 8 to 30 days.  
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Introduction 
Infection with Helicobacter pylori (H pylori), a bacterium that frequently colonizes the human stomach, is a strong and causal risk factor for 
peptic ulcer disease and gastric cancer [1-3]. Worldwide, 95% of duodenal and 70% of gastric ulcers are associated with H pylori [4]. In Sweden, 
the prevalence of H pylori among adults is approximately 30%, which is lower than in most countries [5]. A peptic ulcer diagnosis with a positive 
test for H pylori is the main indication for H pylori eradication therapy, which usually includes treatment with 2 antibiotics and a proton pump 
inhibitor (PPI). However, not all patients hospitalized for peptic ulcer disease have their H pylori infection confirmed whilst hospitalized, and 
subsequently do not always receive H pylori eradication therapy shortly after the peptic ulcer diagnosis. Instead, these patients are initially only 
prescribed a PPI, which does not eradicate H pylori. Delays in eradication therapy can be due to several reasons, including forgetfulness, false 
negative tests for H pylori [6], lack of biopsy samples (eg, in situations with emergency bleeding or perforation) or H pylori resistance (an 
increasing problem worldwide) [7]. In fact, an earlier review from the Swedish Council on Health Technology Assessment has shown that only 
43% of patients hospitalized for peptic ulcer bleeding in Sweden did not receive H pylori eradication therapy within 90 days of diagnosis [8]. 
The consequences of delays in H pylori eradication therapy regarding risk of recurrent ulcer or gastric cancer are unclear. The scarce literature 
examining these issues has indicated that delays >120 days and >365 days might increase the risk of recurrent ulcer [9] and gastric cancer, 
respectively [10].  
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We aimed to test the hypothesis that various lengths of delays in H pylori eradication therapy increase the risk of recurrent peptic ulcer 
disease, complicated peptic ulcer disease, and gastric cancer in a large and population-based cohort study.  
 
Materials and methods 
Design 
This nationwide and population-based cohort study included all adults (≥18 years) diagnosed with peptic ulcer and receiving H pylori 
eradication therapy in Sweden during the study period July 1, 2005 to December 31, 2013. The study exposure was various predefined time 
latencies between peptic ulcer diagnosis and H pylori eradication therapy and the outcomes were recurrent peptic ulcer, peptic ulcer 
complicated by perforation or bleeding, and gastric cancer. The study was approved by the Regional Ethical Review Board in Stockholm 
(number 2014/1291-31/4).  
 
Cohort members 
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All members of the study cohort had peptic ulcer disease and H pylori eradication therapy during the study period. Patients with gastric cancer 
diagnosis before or within 1 year of the index hospitalization for peptic ulcer were excluded, as were patients with Zollinger-Ellison syndrome 
(a gastrin-secreting pancreatic tumor).  
Data on peptic ulcer disease and H pylori eradication therapy were retrieved from the Swedish Patient Registry and the Swedish Prescribed 
Drug Registry, respectively. The Patient Registry held data on all diagnoses recorded at hospitalizations and out-clinic specialist care in Sweden 
during the entire study period. The diagnosis codes K25-K27 in the 10
th
 version of the International Classification of Diseases (ICD-10) were 
used to define peptic ulcer disease. The completeness of main diagnoses is approximately 95% in this registry [11]. Diagnoses of gastric and 
duodenal ulcers are supposed to be confirmed by endoscopy according to Swedish guidelines, and indeed the Swedish Cancer Registry, which 
records 98% of all diagnosed gastric cancer cases, has 100% completeness of histological verification of these tumors [12]. The Prescribed Drug 
Registry records all prescribed and dispensed drugs in Sweden (approximately 9.5 million inhabitants) since July 1, 2005 [13]. This registry 
contains information on names of prescribed drug substances according to the anatomical therapeutic chemical classification (ATC) [13]. H 
pylori eradication therapy was defined according to ATC-codes representing the standard recommendations for eradication therapy in Sweden: 
A02BC (PPI) and any two of J01CA04 (amoxicillin) or J01FA09 (clarithromycin) or J01XD (metronidazole), including the only combination 
package for eradication therapy available in Sweden, ie, A02BD06 (Nexium HP). Included were also combinations that are recommended 
whenever primary eradication therapy fails: PPIs + metronidazole + doxycycline (J01AA02) + bismuth (A02BX05) or PPIs + amoxicillin + 
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levofloxacin (J01MA12). All antibiotic prescriptions needed to be dispensed at the same date to fulfil the inclusion criteria. For PPIs, a window 
was allowed from 60 days before to 5 days after the antibiotic prescription because many people already have PPIs prescribed and for 
continuous use the standard package is for 100 days of use.  
 
Exposure definition 
The exposure was defined as the time interval between the date of peptic ulcer diagnosis and the date of eradication therapy of H pylori, which 
was categorized into 5 predefined groups: ≤7 days, 8 to 30 days, 31 to 60 days, 61 to 365 days, and >365 days. The choice of time intervals was 
pre-defined and based on clinical relevance. The index episode of peptic ulcer was the first one occurring during the study period. For patients 
with several treatments to accomplish H pylori eradication, the latest treatment during the study period was counted as the eradication 
therapy occasion. 
 
 Outcome definition 
There were 3 outcomes: (1) recurrence of peptic ulcer occurring >30 days after the index peptic ulcer diagnosis (a peptic ulcer diagnosis within 
30 days from the index peptic ulcer was defined as the same peptic ulcer), (2) peptic ulcer complicated by bleeding or perforation >30 days 
after the index diagnosis, and (3) gastric cancer occurring >1 year after the index peptic ulcer diagnosis. Recurrent ulcer was defined by the ICD-
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10 codes K25-K27 as recorded in the Patient Registry. Ulcers complicated with perforation or bleeding were defined by the ICD-10 codes K25.0-
2, K25.4-6, K26.0-2, K26.4-6, K27.0-2, and K27.4-6 in the Patient Registry. The Swedish Cancer Registry was used to assess gastric cancer with 
the ICD-10 code C16. The Swedish Cancer Registry has 98% complete registration of type and date of gastric cancer diagnoses in Sweden [12].  
 
Censoring 
Censoring of follow-up for mortality or migration was enabled by collecting data from the Swedish Registry of the Total Population, which 
provided complete information on dates of death and emigration for all cohort members with a maximum delay of 14 days [14].  
 
Confounders 
Selected as potential confounding factors were age, sex, comorbidity, history of ulcer disease, use of ulcerogenic drugs, and use of PPIs. Data 
on age, sex, comorbidities and history of ulcer disease were retrieved from the Patient Registry. Comorbidity was defined using the most 
updated version of the Charlson Comorbidity Index, which has been developed and well validated to enhance international transferability using 
register data for weighting comorbidity and provide comorbidity scores for each individual [15]. Information about all diagnoses included in the 
Charlson Comorbidity Index was retrieved from the Patient Registry. Ulcer history was defined by an ulcer diagnosis (ICD-7 codes 540-541, ICD-
8 codes 531-533, ICD-9 codes 531-533, and ICD-10 codes K25-K27) recorded >30 days before the index ulcer diagnosis in the Patient Registry. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
   
9 
 
Use of ulcerogenic drugs was defined as ≥2 prescriptions of any of the following medications after the date of the index ulcer: aspirin (ATC-code 
B01AC and N02BA01), other nonsteroidal anti-inflammatory drugs (NSAIDs) (ATC-codes M01AB, M01AC, M01AE and M01AH) or clopidogrel 
(ATC-code B01AC04). This definition was chosen to include individuals with more or less regular use of the drug under study, not individuals 
who used the drug occasionally. Use of PPIs was defined as ≥2 prescriptions of PPIs (ATC-code A02BC) between the index ulcer date and 
recurrent ulcer or gastric cancer or the end of the study, in addition to the PPIs that were prescribed during the H pylori eradication therapy. 
Data on use of ulcerogenic drugs and PPIs were retrieved from the Prescribed Drug Registry. 
Statistical analysis 
Cox proportional hazard regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). H pylori eradication 
therapy within 7 days after peptic ulcer diagnosis was the reference category in all analyses. Multivariable models were created to adjust for 
age (continuous variable), sex (male or female), comorbidity (Charlson Comorbidity Index score 0, 1, or ≥2) [15], and ulcer history (yes or no). In 
the analysis examining recurrence of peptic ulcer, we further adjusted for use of ulcerogenic drugs (yes or no) and PPIs (yes or no). Follow-up 
continued until death, emigration, date of recurrent peptic ulcer (with or without adverse event), date of gastric cancer, or end of the study 
period (December 31, 2013), whichever occurred first. To evaluate potential interactions, stratified analyses were conducted for each of the 
potential confounders included in the multivariable model. All analyses were performed using the statistical software IBM SPSS Statistics for 
Windows, Version 23.0 (Armonk, NY: IBM Corp). 
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Results 
Patients 
In total, 29,032 patients with peptic ulcer who had H pylori eradication therapy were included in the final study cohort. During the mean 
follow-up time of 75 months (2268 days), 7629 patients had recurrent peptic ulcer, 2050 had peptic ulcer adverse events, and 50 patients 
developed gastric cancer. Characteristics of the study participants are shown in Table 1. More than half of the patients were men (57.0%). A 
slight majority of the patients (65.8%) received H pylori eradication therapy ≤7 days after the peptic ulcer diagnosis. Comparing the patients in 
the five different time latency categories, there were only minor differences in the crude frequencies of age, sex, and comorbidity, whereas the 
use of ulcerogenic drugs and PPIs (outside the eradication therapy period) differed more. Tobacco-related disorders were evenly distributed 
across categories of lengths of delays in H pylori eradication therapy. Alcohol-related disorders were similar for the first categories of delays, 
but were slightly more common in the last 2 categories of delay. Contacts with healthcare (for any indication) were slightly higher in the last 
two delay categories (Table 1).  
 
Risk of recurrent peptic ulcer 
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The risk of recurrent peptic ulcer increased for each longer time latency category between the primary peptic ulcer diagnosis and H pylori 
eradication therapy (Table 2). Compared to patients with H pylori eradication therapy within 7 days of diagnosis, patients receiving eradication 
therapy 8-30 days after diagnosis had a 17% increased risk of recurrent ulcer (HR 1.17; 95% CI, 1.08-1.25). The HRs increased for each longer 
latency category, and the HR was over 3-fold in the patients treated with H pylori eradication therapy >365 days after ulcer diagnosis (HR 3.55; 
95% CI, 3.33-3.79).  
Stratification for age showed that patients below the mean age had a slightly higher risk of recurrent ulcer than patients above the mean age 
(Table 3). Results were similar for men and women. The risk of recurrent ulcer with delayed H pylori eradication therapy was higher among 
patients with no comorbidities than those who had comorbid conditions. Users of ulcerogenic drugs had an increasing risk over time compared 
with non-users, in those with >60 days latency interval. Patients with PPI use outside the eradication therapy period also had a more 
pronounced increase in risk with latencies >60 days than patients not taking such medication (Table 3). In analyses stratified for inpatient or 
outpatient care at index diagnosis, the results remained similar in both groups (Supplementary Table 1). Stratification for duodenal or gastric 
ulcer showed a more pronounced increase in risk for duodenal ulcers, but the dose-response association remained, regardless of ulcer location 
(Table 3). 
 
Risk of peptic ulcer with perforation or bleeding 
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Even stronger associations were found between time delays of H pylori eradication therapy and risk of peptic ulcer complicated by perforation 
or bleeding (Table 2). Compared with patients receiving H pylori eradication therapy within 7 days after peptic ulcer diagnosis, those with H 
pylori eradication therapy between 8 and 30 days after a peptic ulcer diagnosis had a 55% increased risk of complicated ulcer (HR 1.55; 95% CI, 
1.35-1.78). The HRs increased for each longer latency category to an over 6-fold risk in patients with eradication therapy delayed by >365 days 
(HR 6.14; 95% CI, 5.47-6.89). Stratified analyses showed higher HRs in older age groups for latency intervals >60 days, whereas no major 
differences were found between the sexes (Table 3). The risk of ulcer adverse events with long delay in H pylori eradication therapy was higher 
among patients with no comorbidities than those who had comorbid conditions. Among patients using ulcerogenic drugs, as well as among 
patients with PPI-use outside the eradication therapy period, the risk of ulcer adverse events was higher with delayed eradication therapy 
compared with patients not using these drugs (Table 3). 
 
Risk of gastric cancer 
The risk of gastric cancer was increased in latency intervals of >60 days between peptic ulcer and eradication therapy (Table 2). Compared with 
patients receiving H pylori eradication therapy within 7 days after peptic ulcer diagnosis, patients receiving eradication therapy 61 to 365 days 
after a peptic ulcer diagnosis had an over 3-fold increased HR of gastric cancer (HR 3.64; 95% CI, 1.55-8.56) and the HR was nearly 5-fold 
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increased with >365 days delay (HR 4.71; 95% CI, 2.36-9.38). Robust stratification analyses were not possible for gastric cancer due to the 
limited number of events. Thus, gastric cancer was not included in Table 3.   
Discussion 
This study indicates strong and time-dependent associations between increased lengths of delay in H pylori eradication therapy after peptic 
ulcer and risks of peptic ulcer recurrence, ulcer adverse events and possibly gastric cancer. The risk of recurrent ulcer and ulcer adverse events 
increased already after an 8- to 30-day delay, whereas the risk of gastric cancer was increased after a delay of 61 to 365 days.  
 
Methodological strengths include the population-based design with an unselected cohort of virtually all eligible patients in Sweden, accuracy 
and completeness of data on exposures and outcomes, adjustment of several potential confounders, completeness of follow-up, and the large 
sample size allowing analyses of several time latency categories. As in any observational study, a limitation is the potential influence of 
unknown confounding. Direct data on the lifestyle factors tobacco smoking and alcohol overconsumption were for example not available. 
However, the adjustment for comorbidities included conditions related to these exposures, ie, chronic obstructive lung disease and liver 
cirrhosis, which should reduce any confounding by these factors. Another issue might be misclassification of relevant medications due to that 
some medications obtained over-the-counter could not be taken in to account. However, this should not influence the results much because 
antibiotics are not sold over the counter in Sweden, and PPIs and ulcerogenic drugs are much more expensive to buy over the counter. Another 
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source of error is the lack of data on how H pylori infection was determined in each case. However, any such misclassification should be at 
random and therefore only dilute associations and not explain the positive associations of this study. The time intervals of delay were chosen 
based on earlier research. We cannot exclude that this can lead to some overestimation of early recurrences in patients with gastric ulcer at 
index diagnosis because these patients usually undergo a repeat endoscopy within 6 to 8 weeks. However, when results are stratified for ulcer 
location, the increased recurrence risk is more pronounced for duodenal ulcers than for gastric ulcers, making it unlikely that a possible slight 
overestimation would much affect the results. Also, any potential misclassification due to this would be nondifferential, ie, be similar in 
patients having had delayed eradication therapy or not and thus rather dilute than explain the association. The length of follow-up for 
recurrent ulcer and ulcer adverse events was sufficient, but for gastric cancer a longer follow-up would have been preferable and stratified 
analyses were not possible. Nevertheless, the HRs of gastric cancer in the main analyses were statistically significantly increased for the longer 
time delay categories in this study. Yet, the results for gastric cancer should be interpreted cautiously. The MALT lymphomas, a special group of 
gastric tumors that are well documented to be associated with H pylori infection, were too few to be analyzed in this material. 
 
The association between time delays in H pylori eradication therapy and risk of recurrent ulcer has, to the best of our knowledge, only been 
examined in 2 previous studies. A retrospective cohort study from Taiwan compared “early” (≤120 days) and “late” (>120 days) eradication 
therapy among 1,900 patients with peptic ulcer hospitalization, and found an increased risk of recurrent ulcer after late eradication therapy 
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(HR 1.52; 95% CI, 1.13-2.04) [9]. The same research group also examined the effect of the 120 days latency within a group of patients with end-
stage renal disease and found similar results, with a lower risk of recurrence in the early eradication therapy group (HR 0.76; 95% CI, 0.64-0.91) 
[16]. The present study, with a 15-fold larger number of patients supports the results of these previous studies. Importantly, this study also 
adds the dimension of a time-dependent pattern with risks of recurrent ulcer associated with both shorter and longer delays in H pylori 
eradication therapy.  
 
The finding of an increased risk of complicated ulcer disease associated with delays in H pylori eradication therapy is new. It is possible that H 
pylori infection interacts with endogenous factors in the patients that increase the risk of recurrence of adverse events. A certain genotype of 
the plasminogen activator inhibitor type 1 that suppresses fibrinolysis is, for example, associated with recurrence of peptic ulcer bleeding [17].  
 
The hypothesis that delayed eradication therapy increases the risk of gastric cancer was proposed in a Taiwanese study, showing that among 
80,255 patients with a >365 days delay of eradication therapy the risk of gastric cancer was 36% increased compared to the general population, 
whereas patients receiving H pylori eradication therapy within 365 days experienced no increase [10]. These findings are partly consistent with 
the results of the present study, although this study shows that even shorter delays (61-365 days) could increase the risk of gastric cancer. It 
has earlier been suggested that long-term use of PPI can increase the risk of gastric cancer, which is supported by a recent large cohort study 
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from Hong Kong [18]. In our study, PPI use outside the eradication period was considered at confounding factor and was adjusted for in all 
models. H pylori infection contributes to the development of peptic ulcer and gastric cancer by inducing chronic inflammation and atrophy of 
the gastric mucosa, and cancer development is further promoted by genetic changes in the gastric epithelial cells. H pylori infection is 
suggested to be a promoter, rather than an initiator in the causal chain that leads to cancer of the stomach [19]. A randomized trial from China 
found that in patients without precancerous gastric lesions, the risk of gastric cancer was decreased after H pylori eradication therapy [20]. A 
recent meta-analysis from our group found a protective effect of H pylori eradication therapy on gastric cancer risk [21]. It is possible that the 
series of events after H pylori infection leading to a peptic ulcer represents an increased inflammatory and cell damaging activity that can 
ultimately promote cancer development. If this process is inhibited by eradication therapy at an early stage, both recurrent ulcer and cancer 
may be prevented. This stresses the need for early detection and eradication of H pylori infection among peptic ulcer patients, a notion 
supported by the findings of the present study.  
 
This study is the first to show a consistent time-dependent association between increased time latencies in H pylori eradication therapy and the 
risk of recurrent ulcer, ulcer adverse events, as well a possible association with gastric cancer. These findings, together with the available 
previous literature and the biological plausibility, argue in favor of causality, but more large-scale studies are needed to confirm these findings 
in other populations. Yet, assuming that the findings of the present study are correct, calculations of the population attributable risk show that 
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23% of recurrent ulcers, 33% of complicated ulcers, and 30% of gastric cancers could be avoided if all patients received eradication therapy 
within 30 days from their initial peptic ulcer diagnosis.  
 
It is notable that delays of H pylori eradication therapy are not uncommon, particularly in light of the well-functioning and all-encompassing 
healthcare system in Sweden, which is accessible for all residents almost without any cost and without private insurance. The reasons for 
delayed eradication therapy are not clear, but in the absence of strong contra-indications for such eradication therapy, factors that might 
contribute include forgetfulness, false negative tests for H pylori, lack of biopsy samples, or H pylori resistance. The strengths of the 
associations between delays in eradication therapy resulting in increased risks of ulcer recurrence, ulcer adverse events and also gastric cancer 
indicate a need to make efforts to reduce such delays. The Swedish Prescribed Drug Registry was initiated in 2005, and earlier data on 
eradication therapy are unfortunately not available. However, the prevalence of antibiotic resistance is very low in Sweden. A systematic 
review from 2010 showed that Sweden had the lowest prevalence of H pylori clarithromycin resistance of all investigated countries, only 1.5% 
[22] As false negative tests of H pylori are common in emergency situations [6], it is advisable to re-test patients with a negative H pylori test in 
the emergency setting. The re-testing should be performed in close proximity to the primary ulcer diagnosis, with PPI-medication withdrawn 2 
weeks before testing, to avoid false negative results due to transformation into coccoid form of H pylori caused by PPI. Advocating a more 
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liberal attitude toward eradication therapy in patients with peptic ulcer, even in the absence of proven H pylori infection, might even be 
justified.  
 
In conclusion, this large and population-based cohort study shows that the length of delay in H pylori eradication therapy after peptic ulcer 
diagnosis is strongly and time-dependently associated with an increased risk of recurrent ulcer and even more so the risk of complicated peptic 
ulcer. Longer delays in eradication therapy can possibly also increase the risk of gastric cancer. These findings emphasize the relevance of 
implementing safe clinical strategies to expedite H pylori eradication associated with peptic ulcer disease.  
References 
[1] Kurata JH, Nogawa AN. Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and 
smoking. J Clin Gastroenterol. 1997;24:2-17. 
[2] Hansson LE, Nyren O, Hsing AW, Bergstrom R, Josefsson S, Chow WH, et al. The risk of stomach cancer in patients with gastric or 
duodenal ulcer disease. N Engl J Med. 1996;335:242-9. 
[3] Rugge M. Gastric Cancer Risk in Patients with Helicobacter pylori Infection and Following Its Eradication. Gastroenterol Clin North 
Am. 2015;44:609-24. 
[4] Ford AC, Gurusamy KS, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive 
people. Cochrane Database Syst Rev. 2016;4:CD003840. 
[5] Storskrubb T, Aro P, Ronkainen J, Wreiber K, Nyhlin H, Bolling-Sternevald E, et al. Antimicrobial susceptibility of Helicobacter pylori 
strains in a random adult Swedish population. Helicobacter. 2006;11:224-30. 
[6] Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and 
meta-analysis. Am J Gastroenterol. 2006;101:848-63. 
[7] Jodlowski TZ, Lam S, Ashby CR, Jr. Emerging therapies for the treatment of Helicobacter pylori infections. Ann Pharmacother. 
2008;42:1621-39. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
   
19 
 
[8] Assessment SSCoHT. Blödande magsår. En systematisk litteraturöversikt - SBU. Swedish Council on Health Technology Assessment, 
SBU; 2011. 
[9] Chang SS, Hu HY. Helicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers 
in Peptic Ulcer Bleeding Patients. Gut Liver. 2015;9:346-52. 
[10] Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients 
with peptic ulcer disease. Gastroenterology. 2009;137:1641-8 e1-2. 
[11] Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al. External review and validation of the Swedish 
national inpatient register. BMC Public Health. 2011;11:450. 
[12] Ekstrom AM, Signorello LB, Hansson LE, Bergstrom R, Lindgren A, Nyren O. Evaluating gastric cancer misclassification: a potential 
explanation for the rise in cardia cancer incidence. J Natl Cancer Inst. 1999;91:786-90. 
[13] Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug 
Register--opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 
2007;16:726-35. 
[14] Ludvigsson JF, Almqvist C, Bonamy AK, Ljung R, Michaelsson K, Neovius M, et al. Registers of the Swedish total population and their 
use in medical research. Eur J Epidemiol. 2016;31:125-36. 
[15] Armitage JN, van der Meulen JH, Royal College of Surgeons Co-morbidity Consensus G. Identifying co-morbidity in surgical patients 
using administrative data with the Royal College of Surgeons Charlson Score. Br J Surg. 2010;97:772-81. 
[16] Chang SS, Hu HY. Association between early Helicobacter pylori eradication and a lower risk of recurrent complicated peptic ulcers 
in end-stage renal disease patients. Medicine (Baltimore). 2015;94:e370. 
[17] Kim HS, Hwang KY, Chung IK, Park SH, Lee MH, Kim SJ, et al. Tissue plasminogen activator and plasminogen activator inhibitor type 
1 gene polymorphism in patients with gastric ulcer complicated with bleeding. J Korean Med Sci. 2003;18:58-64. 
[18] Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer 
development after treatment for Helicobacter pylori: a population-based study. Gut. 2017. 
[19] Tsukamoto T, Toyoda T, Mizoshita T, Tatematsu M. Helicobacter pylori infection and gastric carcinogenesis in rodent models. Semin 
Immunopathol. 2013;35:177-90. 
[20] Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-
risk region of China: a randomized controlled trial. Jama. 2004;291:187-94. 
[21] Doorakkers E, Lagergren J, Engstrand L, Brusselaers N. Eradication of Helicobacter pylori and Gastric Cancer: A Systematic Review 
and Meta-analysis of Cohort Studies. J Natl Cancer Inst. 2016;108. 
[22] De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. pylori antibiotic resistance: a systematic 
review. J Gastrointestin Liver Dis. 2010;19:409-14. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
   
20 
 
 
Table 1. Characteristics of the study cohort members, consisting of patients with peptic ulcer diagnosis, treated with 
Helicobacter pylori eradication in Sweden in 2005-2013, presented as number (%).  
    
Time latency categories in Helicobacter pylori eradication after peptic ulcer    
Number of patients (%)   
    
Total 
cohort     
≤ 7 days          8-30 days 31-60 days  
61-365 
days  
>365 days           
Total number 
  
29 032  
(100%) 
19 089 (65.8%) 
4 141 
(14.3%) 
1 407   
(4.8%) 
2 193  
(7.6%) 
2 202  
(7.6%) 
Number of ulcer events 7629 3798 936 535 1130 1230 
Number of complicated ulcer 
events 
2050 826 276 158 326 464 
Number of gastric cancer 
events 
50 23 5 2 7 13 
Mean age (years)   64.6 63.9 70.0 67.0 63.4 59.9 
Sex 
Male  16 549 11 226 2199 736 1 219 1169 
  (57.0%) (58.8%) (53.1%) (52.3%) (55.6%) (53.1%) 
Female 12 483 7863 1942 671 974 1 033 
    (43.0%) (41.2%) (46.9%) (47.7%) (44.4%) (46.9%) 
Charlson 
comorbidity score 
0 10474 7454 1070 439 721 790 
   (36.1%)  (39.0%)  (25.8%) (31.2%) (32.9%) (35.9%) 
1 6905 4456 1013 350 529 557 
     (23.8%) (23.3%)  (24.5%) (24.9%) (24.1%)  (25.3%) 
  >1 11653 7179 2058 618 943 855 
    (40.1%)  (37.6%)  (49.7%) (43.9%) (43.0%) (38.8%) 
Use of ulcerogenic 
drugs 
Yes 10 871 7 251 1 496 482 688 954 
 (37.4%) (38.0%)  (36.1%) (34.3%) (31.4%) (43.3%) 
No 18 161 11 838 2 645 925 1 505 1 248 
    (62.6%) (62.0%) (63.9%)  (65.7%)  (68.6%)  (56.7%) 
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Use of proton 
pump inhibitors 
outside 
eradication period 
Yes 12 895 8 059 2 066 574 934 1 262 
 (44.4%) (42.2%)  (49.9%) (40.8%) (42.6%)  (57.3%) 
No 16 137 11 030 2 075 833 1 259 940 
  (55.6%)  (57.8%)  (50.1%) (59.2%)  (57.4%) (42.7%) 
Tobacco related 
diseases 
Yes 2 603 1 560 449 137 238 219 
(9%) (8.2%) (10.8%) (9.7%) (10.9%) (9.9%) 
No 26 429 17 529 3 692 1 270 1 955 1 983 
  (91%) (91.8%) (89.2%) (90.3%) (89.1%) (90.1%) 
Alcohol related 
diseases 
Yes 2 422 1 425 358 112 234 293 
(8.3%) (7.5%) (8.6%) (8.0%) (10.7%) (13.3%) 
No 26 610 17 664 3 783 1 295 1 959 1 909 
  (91.7%) (92.5%) (91.4%) (92.0%) (89.3%) (86.7%) 
Mean number of health care 
visits during the study period 
(standard deviation)  
32.1 
(40.8) 
29.7 
(36.9) 
33.2 
(44.4) 
31.8 
(48.9) 
38.8 
(48.5) 
44.5 
(48.4) 
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Table 2. Latency intervals between peptic ulcer and Helicobacter pylori eradication therapy in relation to risk of recurrent peptic ulcer, ulcer complicated by 
bleeding or perforation and gastric cancer, expressed as hazard ratios (HR) and confidence intervals (CI) 
  
Recurrent ulcer Complicated ulcer Gastric cancer 
  
Latency     
interval 
Number of 
cases 
(person 
years) 
Crude HR          
(95% CI) 
Adjusted HR*            
(95% CI) 
Number of 
cases 
(person 
years) 
Crude HR          
(95% CI) 
Adjusted HR*           
(95% CI) 
Number of 
cases 
(person 
years) 
Crude HR           
(95% CI) 
Adjusted HR*       
(95% CI) 
≤ 7 days 3 798 (2 035) 1.00 (reference) 826 (509) 1.00 (reference) 23 (46) 1.00 (reference) 
8-30 days 936 (452) 1.21 (1.13-1.30) 1.17 (1.08-1.25) 276 (128) 1.66 (1.44-1.90) 1.55 (1.35-1.78) 5 (5) 1.15 (0.44-3.03) 0.85 (0.32-2.23) 
31-60 days 535 (136) 2.30 (2.10-2.52) 2.37 (2.16-2.59) 158 (41) 3.13 (2.64-3.71) 3.19 (2.69-3.78) 2 (0) 1.47 (0.35-6.22) 1.31 (0.31-5.54) 
61-365 days 1 130 (466) 3.04 (2.84-3.25) 2.96 (2.76-3.16) 326 (139) 4.08 (3.59-4.64) 4.00 (3.51-4.55) 7 (8) 3.77 (1.62-8.81) 3.64 (1.55-8.56) 
>365 days 1 230 (2 188) 2.75 (2.58-2.93) 3.55 (3.33-3.79) 464 (786) 4.77 (4.25-5.34) 6.14 (5.47-6.89) 13 (29) 4.72 (2.39-9.32) 4.71 (2.36-9.38) 
p for trend 
 
<0.001 <0.001   <0.001 <0.001   <0.001 <0.001 
* Adjusted for age, sex, comorbidity, history of ulcer disease, use of ulcerogenic drugs and use of proton pump inhibitors.  
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Table 3. Stratified analyses of latency interval between peptic ulcer and Helicobacter eradication in relation to risk 
of recurrent peptic ulcer and complicated ulcer, expressed as hazard ratios (HR) and confidence intervals (CI). 
Analyses stratified for age, sex, comorbidity, use of ulcerogenic drugs, use of proton pump inhibitor (PPI) and ulcer 
location. 
Stratification variable Time latency categories in Helicobacter pylori eradication after peptic ulcer   
Risk of recurrent ulcer 
≤ 7 days              8-30 days  31-60           days  61-365 days  >365 days            
HR* (95% CI) HR* (95% CI) HR* (95% CI) HR* (95% CI) HR* (95% CI) 
Age                     < Mean 
1.00 
(reference) 
1.29 (1.14-1.47) 2.44 (2.09-2.85) 3.32 (2.99-3.68) 4.07 (3.71-4.47) 
                            ≥ Mean 
1.00 
(reference) 
1.14 (1.04-1.24) 2.28 (2.04-2.55) 2.70 (2.47-2.95) 2.98 (2.72-3.27) 
Sex 
Male  
1.00 
(reference) 
1.16 (1.05-1.28) 2.19 (1.93-2.50) 2.90 (2.64-3.17) 3.62 (3.32-3.96) 
Female 
1.00 
(reference) 
1.18 (1.06-1.31) 2.55 (2.25-2.90) 3.02 (2.74-3.34) 3.44 (3.13-3.80) 
Charleson 
Comorbidity 
Index 
0 
1.00 
(reference) 
1.30 (1.12-1.50) 2.50 (2.11-2.98) 3.55 (3.14-4.02) 4.69 (4.17-5.27) 
1 
1.00 
(reference) 
1.20 (1.04-1.39) 2.69 (2.27-3.20) 3.00 (2.61-3.45) 3.54 (3.10-4.03) 
>1 
1.00 
(reference) 
1.10 (1.00-1.22) 2.10 (1.83-2.40) 2.70 (2.41-2.93) 2.84 (2.57-3.13) 
Use of 
ulcerogenic Yes 
1.00 
(reference) 
1.11 (0.91-1.36) 1.10 (0.79-1.53) 4.69 (3.95-5.56) 6.60 (5.78-7.53) 
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drugs 
No 
1.00 
(reference) 
1.17 (1.08-1.27) 2.57 (2.34-2.83) 2.65 (2.46-2.85) 2.93 (2.72-3.17) 
Use of PPI 
besides 
eradication 
period 
Yes 
1.00 
(reference) 
1.28 (1.08-1.51) 1.20 (0.89-1.61) 3.86 (3.30-4.52) 5.74 (5.09-6.49) 
No 
1.00 
(reference) 
1.16 (1.07-1.25) 2.59 (2.36-2.85) 2.62 (2.43-2.82) 2.75 (2.54-2.99) 
Gastric ulcer 
1.00 
(reference) 
1.01 (0.91-1.11) 1.65 (1.47-1.85) 2.18 (1.99-2.39) 2.41 (2.18-2.67) 
Duodenal ulcer 
1.00 
(reference) 
1.24 (1.11-1.37) 3.34 (2.89-3.86) 3.76 ( 3.41-4.15) 4.65 (4.27-5.06) 
  
Risk of recurrent ulcer adverse events 
HR* (95% CI) HR* (95% CI) HR* (95% CI) HR* (95% CI) HR* (95% CI) 
Age                     < Mean 
1.00 
(reference) 
1.58 (1.23-2.04) 2.98 (2.19-4.07) 4.67 (3.81-5.71) 6.82 (5.73-8.10) 
                            ≥ Mean 
1.00 
(reference) 
1.55 (1.32-1.83) 3.23 (2.63-3.97) 3.61 (3.05-4.28) 5.41 (4.62-6.34) 
Sex 
Male  
1.00 
(reference) 
1.56 (1.30-1.88) 3.04 (2.40-3.84) 3.99 (3.37-4.73) 6.60 (5.69-7.66) 
Female 
1.00 
(reference) 
1.54 (1.25-1.90) 3.36 (2.62-4.31) 4.02 (3.29-4.92) 5.53 (4.61-6.65) 
Charleson 
Comorbidity 
Index 
0 
1.00 
(reference) 
1.77 (1.32-2.40) 3.72 (2.65-5.21) 5.04 (3.89-6.52) 9.55 (7.72-11.88) 
1 
1.00 
(reference) 
1.70 (1.30-2.22) 3.19 (2.27-4.48) 3.97 (3.05-5.18) 5.77 (4.56-7.31) 
>1 
1.00 
(reference) 
1.39 (1.15-1.68) 2.88 (2.26-3.68) 3.60 (3.00-4.31) 4.72 (3.99-5.59) 
Use of 
ulcerogenic Yes 
1.00 
(reference) 
1.02 (0.68-1.54) 0.81 (0.38-1.73) 5.83 (4.26-7.97) 10.02 (7.92-12.68) 
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drugs 
No 
1.00 
(reference) 
1.64 (1.42-1.90) 3.67 (3.08-4.38) 3.59 (3.12-4.14) 5.19 (4.53-5.94) 
Use of PPI 
besides 
eradication 
period 
Yes 
1.00 
(reference) 
1.43 (1.04-1.95) 1.63 (0.99-2.67) 4.47 (3.34-5.97) 8.43 (6.78-10.48) 
No 
1.00 
(reference) 
1.60 (1.37-1.86) 3.57 (2.98-4.28) 3.62 (3.14-4.19) 5.02 (4.36-5.79) 
Gastric ulcer 
1.00 
(reference) 
1.16 (0.94-1.45) 2.21 (1.73-2.81) 2.87 (2.36-3.49) 4.19 (3.43-5.11) 
Duodenal ulcer 
1.00 
(reference) 
1.90 (1.59-2.27) 5.01 (3.94-6.37) 5.38 (4.52-6.40) 7.69 (6.66-8.87) 
* Adjusted for age, sex, comorbidity index, use of ulcerogenic drugs and use of PPI, when applicable 
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Supplementary table. Latency intervals between peptic ulcer and Helicobacter 
pylori eradication in relation to risk of recurrent peptic ulcer and ulcer 
complicated by bleeding or perforation, expressed as hazard ratios (HR) and 
confidence intervals (CI). Stratified for inpatient or outpatient care at index 
diagnosis. 
  
Inpatient care at index diagnosis 
  Recurrent ulcer Complicated ulcer 
Latency interval 
Adjusted HR*                           
(95% CI) 
Adjusted HR*                             
(95% CI) 
≤7 days 1.00 (reference) 1.00 (reference) 
8-30 days 1.20 (1.10-1.31) 1.50 (1.30-1.74) 
31-60 days 2.46 (2.19-2.76) 3.21 (2.66-3.88) 
61-365 days 2.86 (2.62-3.12) 3.59 (3.10-4.15) 
>365 days 3.60 (3.30-3.93) 5.75 (5.02-6.58) 
  
Outpatient care at index diagnosis 
  
Recurrent ulcer Complicated ulcer 
Latency interval 
Adjusted HR*                           
(95% CI) 
Adjusted HR*                            
(95% CI) 
≤7 days 1.00 (reference) 1.00 (reference) 
8-30 days 1.09 (0.95-1.24) 0.82 (0.51-1.32) 
31-60 days 2.22 (1.92-2.57) 2.89 (1.93-4.35) 
61-365 days 3.04 (2.73-3.39) 4.84 (3.62-6.46) 
>365 days 3.52 (3.19-3.88) 8.05 (6.40-10.12) 
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* Adjusted for age, sex, comorbidity, history of ulcer disease, use of ulcerogenic 
drugs and use of proton pump inhibitors. 
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Acronyms in order of appearance 
 
H. pylori - Helicobacter pylori 
HR  - Hazard ratio 
CI  - Confidence interval 
PPI  - Proton pump inhibitor 
ICD  - International Classification of Diseases 
ATC  - Anatomical therapeutic chemical classification 
NSAID  - Non-steroidal anti-inflammatory drug 
 
